GlassScriptPhysician profile
George Adams
NPI 1083860506
$4,539.08
in general payments reported to CMS, 2019-2025
30 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $744 · 2021: $835 · 2022: $781 · 2023: $639 · 2024: $792 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $871.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $757.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $573.08 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $483.89 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $375.61 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $222.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $192.91 | 2019-2025 | |
| Lilly USA, LLC | $177.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $125.52 | 2021-2023 | Camzyos |
| Allergan, INC. | $116.16 | 2020 | |
| Novartis Pharmaceuticals Corporation | $85.51 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $57.56 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.18 | 2021-2022 | |
| Astellas Pharma US INC | $48.18 | 2021-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $40.73 | 2023 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.58 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $35.16 | 2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $31.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.97 | 2021 | |
| Xeris Pharmaceuticals, INC. | $28.73 | 2021 | |
| Daiichi Sankyo INC. | $27.53 | 2020 | |
| Boston Scientific Corporation | $27.51 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.32 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.85 | 2024 | Voquezna |
| Philips North America LLC | $18.76 | 2024 | (Ck7) Extended Holter |
| Exact Sciences Corporation | $16.23 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $15.59 | 2022 | |
| Merck Sharp & Dohme LLC | $14.98 | 2020 | |
| Medtronic, INC. | $14.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.